Microsoft word - englishpublication2012.doc

English Publication of Kazuo Umezawa, 2012. 31st March 2012
Publication of Kazuo Umezawa in 2012. Articles in Japanese are removed, so there 340. E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. Bioorganic & Medicinal 341. T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa, H. Kataoka: Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neuro-Oncology 14: 19-28, 2012. 342. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. Chem. 343. T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N. Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and Satoru Todo: A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. Journal of Crohn’s and Colotis, in press. 344. C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S. Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via NFκB pathway on advanced-stage epithelial 346. M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K. Miyazono: TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW 264.7 macrophage cells. J. Biochem., in press. 347. R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I. Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology, in press. 348. J. A. McCubrey, S. L. Abrams, K. Umezawa, L. Cocco, A. M. Martelli, R. A. Franklin, W. H. Chappell, L. S. Steelman: Novel approaches to target cancer initiating cells–Eliminating the root of the cancer. Advances in Enzyme Regulation, in press. 349. R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R. Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki, and S. Todo: The immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood 350. M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa: Structure-activity relationship 0f 9-methylstreptimidone that induces selective apoptosis in adult T-cell leukemia cells. Oncology Res., in press. 351. M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K. Umezawa: Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB. Org. Biomol. Chem., in press. 352. N. Lampiasi, A. Azzolina1, K Umezawa, G. Montalto, J. A. McCubrey and M. Cervello: The novel NF-kB inhibitor DHMEQ synergizes with Celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer 353. A. M. Castro-Gamero, K. S. Borgesa, V. da Silva Silveira, R. C. P. Lira, R. de Paula G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of nuclear factor-jB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anti-Cancer Drugs, in press. 354. K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa, M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. T and N. Gotoh: ErbB/NFkB signaling controls self-renewal of breast cancer stem cells. Proc. Natl. Acad. Sci. USA, in press.


Wipo arbitration and mediation center

Before the: WORLD INTELLECTUAL PROPERTY ORGANIZATION ARBITRATION AND MEDIATION CENTER LATIN AMERICAN TELECOM, LLC (Objector) TLD string objected to: < .TUBE > (Applicant/Respondent) LEGAL RIGHTS OBJECTION (Applicant Guidebook, Module 3; Procedure, art. 6, 7, 8; WIPO Rules for New gTLD Dispute Resolution, para. 4) I. Introduction [1.] This Legal

Heartstart fr1 philips.indd

• Extremely easy to use • Optimized for challenging environments • Proven therapy Contacto: [email protected] HeartStart FR1 Philips Dimensions Size: 2.53” h x 8.75” w x 8” d (64 mm x 223 mm x 203 mm). Weight: 2 kg (4.4 lbs) with batteries installed Defi brillator Waveform Truncated exponential biphasic. Waveform p

Copyright © 2011-2018 Health Abstracts